Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the prostate

- Metastatic disease (N1 and/or M1)

- Unresponsive or refractory to androgen-deprivation therapy

- Must have received one, and only one, prior taxane-containing (docetaxel or
paclitaxel) chemotherapy regimen for metastatic disease that was discontinued due to
disease progression, intolerance, or patient request

- Evidence of disease progression as defined by ≥ 1 of the following:

- Progression of measurable disease

- Progression of evaluable disease

- Rising prostate-specific antigen (PSA)

- At least 2 consecutive rises in PSA levels, each taken ≥ 7 days apart

- PSA ≥ 5 ng/mL

- Must have pre-study PSA > 5 ng/mL

- Measurable or evaluable disease

- Soft tissue disease that has been irradiated within the past 2 months is not
considered measurable disease

- Soft tissue disease that has been irradiated ≥ 2 months prior to study entry is
considered measurable disease provided the lesion progressed after radiation

- Surgical or medical castration required

- If luteinizing hormone-releasing hormone (LHRH) agonists (leuprolide or
goserelin) or LHRH antagonists (abarelix) were used, then must continue use
during study therapy

- No prior or concurrent brain metastases (treated or untreated)

- If clinical suspicion of brain metastases, must meet the following criteria:

- Brain CT scan or MRI negative for metastatic disease within the past 56
days

- No new symptoms since radiographic evaluation

- Performance status - Zubrod 0-2

- Absolute granulocyte count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 9 g/dL

- Bilirubin normal

- SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN)

- Creatinine ≤ 1.5 times ULN

- Creatinine clearance ≥ 40 mL/min

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- Fertile patients must use effective contraception

- No peripheral neuropathy ≥ grade 2

- No prior allergic reaction attributed to compounds of similar chemical or biological
composition to SB-715992

- No ongoing or active infection

- No psychiatric illness or social situation that would preclude study participation

- No other uncontrolled illness

- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer or adequately treated stage I or II cancer in complete
remission

- No colony-stimulating factors during the first course of study therapy

- No concurrent anticancer biologic therapy

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy and recovered

- See Disease Characteristics

- At least 4 weeks since prior flutamide or ketoconazole

- At least 6 weeks since prior bicalutamide or nilutamide

- No concurrent anticancer hormonal therapy except LHRH agonist or antagonist for
patients who have not undergone orchiectomy

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy and recovered

- Prior samarium Sm 153 lexidronam pentasodium allowed

- No prior strontium chloride Sr 89

- No prior radiotherapy to ≥ 30% of bone marrow

- No concurrent anticancer radiotherapy

- See Disease Characteristics

- At least 3 weeks since prior surgery and recovered

- At least 2 weeks since prior and no concurrent use of any of the following CYP3A4
inhibitors or inducers:

- Clarithromycin

- Erythromycin

- Troleandomycin

- Rifampin

- Rifabutin

- Rifapentine

- Itraconazole

- Ketoconazole

- Fluconazole (dose > 200 mg/day)

- Voriconazole

- Nefazodone

- Fluvoxamine

- Verapamil

- Diltiazem

- Grapefruit juice

- Bitter orange

- Phenytoin

- Carbamazepine

- Phenobarbital

- Oxcarbazepine

- Hypericum perforatum (St. John's wort)

- Modafinil

- At least 6 months since prior and no concurrent amiodarone

- No other investigational drugs for 4 weeks before, during, and for 2 weeks after
study therapy

- No other concurrent anticancer cytotoxic therapy

- No other concurrent anticancer therapy

- No concurrent combination antiretroviral therapy for HIV-positive patients

- Concurrent enrollment on SWOG-9205 (central prostate cancer serum repository
protocol) allowed